OGEN
What one share of Oragenics holds
Pharmaceutical Preparations
Oragenics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.51 |
|---|---|
| Cash and investments | $0.86 |
| Book value | $0.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$47.16 | $0.18 | −$47.76 | — | $18.11 |
| 2017 | $0.00 | −$40.99 | — | −$38.75 | — | $38.45 |
| 2018 | — | −$26.06 | $0.29 | −$21.18 | — | — |
| 2019 | — | −$11.04 | $0.02 | −$9.25 | — | $11.21 |
| 2020 | — | −$14.03 | — | −$9.00 | — | $5.51 |
| 2021 | $0.02 | −$4.17 | $0.01 | −$3.59 | — | — |
| 2022 | $1.96 | −$213.34 | $1.90 | −$229.28 | — | $192.76 |
| 2023 | $0.50 | −$275.45 | — | −$97.22 | — | $30.85 |
| 2024 | — | −$47.88 | — | −$38.95 | — | −$0.51 |
| 2025 | — | −$4.56 | — | −$4.29 | — | $1.94 |